Log in
Enquire now
‌

US Patent 10202365 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors

Patent 10202365 was granted and assigned to Blueprint Medicines on February, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Blueprint Medicines
Blueprint Medicines
Current Assignee
Blueprint Medicines
Blueprint Medicines
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10202365
Patent Inventor Names
Steven Mark Wenglowsky0
Lucian V. DiPietro0
Natasja Brooijmans0
Paul E. Fleming0
Yulian Zhang0
Joseph L. Kim0
Date of Patent
February 12, 2019
Patent Application Number
15548925
Date Filed
February 5, 2016
Patent Citations
‌
US Patent 10000496 Compositions useful for treating disorders related to kit and PDGFR
‌
US Patent 10000490 Inhibitors of the fibroblast growth factor receptor
‌
US Patent 10017512 Compounds and compositions useful for treating disorders related to NTRK
0
Patent Citations Received
‌
US Patent 12060354 Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
0
‌
US Patent 11040979 Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
‌
US Patent 11046697 Compounds and compositions useful for treating disorders related to NTRK
0
‌
US Patent 11059827 Compounds and compositions useful for treating disorders related to NTRK
0
‌
US Patent 11273160 RET inhibitor for use in treating cancer having a RET alteration
0
‌
US Patent 11279688 Inhibitors of RET
‌
US Patent 11872192 RET inhibitor for use in treating cancer having a RET alteration
0
‌
US Patent 11963958 RET inhibitor for use in treating cancer having a RET alteration
0
...
Patent Primary Examiner
‌
Jeffrey H Murray
Patent abstract

Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g., for treating a condition mediated by aberrant RET activity

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10202365 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.